Table 1 Summary of drugs tested for in vitro and in vivo potentiation in combination with electroporation pulses
From: Electrochemotherapy: from the drawing board into medical practice
| Drug tested | In vitro potentiation | In vivo potentiation |
|---|---|---|
| Bleomycin | Yes; 100–5000-fold [1, 17, 18, 26–28] | Yes |
| Cisplatin | Yes; 1.8–12.2-fold [17, 18, 28, 29] | Yes [28–30] |
| Calcium | Yes; more hundred-fold [31, 32] | Yes [31] |
| Netropsin | Yes; 200-fold [1] | – |
| Carboplatin | Yes; 1.6–13-fold [17, 18, 27, 29] | – |
| 2-N-methyl-9-hydroxy-ellipticinium (NMHE) | Yes; 4-fold [1] | – |
| Vincristine | Yes; 1.3–3.4-fold [18] | – |
| ActiNomycin D | Yes; 2–3-fold [1] | – |
| Cytarabine | Yes; 2-fold [18] | – |
| Oxaliplatin | Yes [29] | – |
| Platinum (II) complex 3P-SK | Yes [29] | Yes [29] |
| Platinum (II) complex PtAMP | Yes [29] | – |
| Mitomycin C | Yes but low; 1.3–1.4-fold [18, 33] | – |
| Vinblastine | Yes but low; 1.1–1.3-fold [18] | – |
| 5-fluorouracil | No or low; 1.25-fold [18, 26] | – |
| Paclitaxel | No or low; 1.3-fold [17, 18] | – |
| Doxorubicin | No or low; 0.67–2-fold [17, 18] | – |
| Nimustine hydrochloride (ACNU) | No [27] | – |
| Methotrexate | No [1] | – |
| 9-OH-ellipticine | No [1] | – |
| Didemnin B | No [1] | – |
| Melphalan | No [1] | – |
| Mithramycin | No [1] | – |
| Taxotere | No [1] | – |
| DauNorubicin | No [17] | – |
| Adriamycin | No [32] | No [28] |
| Etoposide | No or ND [17, 18, 27] | – |
| Ancitabine | ND [18] | – |
| Gemcitabine | ND [18] | – |
